AAIC 2018: New National Strategy for recruitment and participation in Alzheimer’s disease trials
A highly detailed 3D rendering of a double helix human DNA in blue color, with small carbon elements and light effects on a dark gray-blue background. The image shows an angle of view of different
The increase of public and private investments in Alzheimer’s disease (AD) research has brought about a proliferation of potential therapeutic targets. However, engagement and participation has not kept pace with the acceleration of research and great need for volunteers. The impact of low participation impedes progress toward generating study results, keeping potentially effective therapies further away from individuals with and at risk for dementia, as well as their caregivers. At the Alzheimer’s Association International Conference (AAIC; 22–26 July, IL, USA), representatives of the National Institutes on Aging (NIA) at the National Institutes of Health (NIH) have reported progress on the...
